Lilly’s Zepbound cuts risk of diabetes by 94% in obese patients, shares gain
Tweet Send to a Friend
Eli Lilly (NYSE: LLY) said Tuesday its weight loss drug reduced the risk of developing type 2 diabetes by 94 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
